Key points are not available for this paper at this time.
MYL9 is upregulated in EOC and may serve as a useful patent of prognostic biomarker in EOC, and it may demonstrate an important value for the clinical treatment and supervision of patients with EOC.
Deng et al. (Sun,) studied this question.